An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms BELIEF
- 07 Jun 2017 Biomarkers information updated
- 11 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
- 11 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.